Recent 8-K filings for RVP
Highest-materiality recent filing
USTR sets 100% tariff on Chinese syringes; Retractable files suit; declares preferred dividend
- USTR finalized 100% tariff on Chinese syringes/needles effective Sept 27, 2024; Retractable sourced 91% from China in H1 2024.
- Retractable filed complaint in U.S. Court of International Trade on Sept 26 to challenge tariff; seeks injunction and to set aside tariff.
-
Retractable Technologies Q2 2026 sales drop 31% to $7.2M; operating loss $5.1M
Q2 2026 net sales $7.2M vs $10.4M in Q2 2025; operating loss $5.1M flat YoY.
-
Retractable Technologies declares preferred dividends for Series II and III
Series II Class B preferred dividend of $39,050.00 declared for Q2 2026.
-
Retractable Technologies Q1 net sales $7.2M (down 13% YoY); operating loss widens to $6.2M
Net sales $7.2M for Q1 2026, down from $8.3M in Q1 2025; net loss $4.2M.
-
Retractable Tech shareholders elect all three Class 2 director nominees at annual meeting
Thomas J. Shaw received 20,777,201 for and 283,312 withheld; elected as Class 2 director.
-
Retractable Technologies cuts workforce ~16% to save $2.2M annually amid tariff concerns
Reduced workforce by ~16%; expects $2.2M annual savings (13% of total workforce costs).
-
Retractable Tech 2025 revenue up 15.8% to $38.3M; operating loss $21.2M; tariff headwinds
Revenue $38.3M (+15.8% YoY); domestic +9.7%, international +64%.
-
Retractable declares $57,611 in preferred dividends for Q4 2025
Series II Class B preferred dividend of $39,050; Series III of $18,561.25.
-
Retractable Q3 net sales $10.1M, operating loss $3.7M; receives Vizient designation
Q3 net sales $10.1M (down from $10.3M YoY); operating loss $3.7M vs $5.1M loss last year.
-
Retractable declares $39,050 and $18,561 dividends to Series II & III preferred holders
Dividends declared: $39,050.00 for Series II, $18,561.25 for Series III Class B Convertible Preferred.
-
Retractable Technologies Q2 net sales up 73% to $10.4M, operating loss narrows to $5.1M
Net sales $10.4M in Q2 2025 (+73% YoY); operating loss narrowed to $5.1M from $5.8M.
-
Retractable Tech reduces workforce 12.4%, expects $1.6M annual savings
Workforce reduction of ~12.4% in manufacturing and support roles; one-time separation payments of ~$56k.
-
Dividends declared on Series II and Series III Class B Convertible Preferred Stock.
-
Moss Adams LLP merged with Baker Tilly US, LLP effective June 3, 2025; Moss Adams resigned as auditor.
-
Retractable Technologies settles lawsuit against Locke Lord for $1.9M
Settlement resolves all claims in Case DC-19-17946 against Locke Lord LLP in Dallas County court.
-
Retractable Q1 net sales $8.3M; operating loss widens to $4.7M on $1.5M tariffs
Total net sales $8.3M vs $7.6M YoY; operating loss $4.7M vs $3.0M YoY.
-
Retractable Tech reduces workforce 7%, saves $1.6M/yr; shift from China due to tariffs
Workforce reduced ~7%; annual savings of $1.6M in wages/benefits (7.8% of workforce costs).
-
Retractable Technologies reports 2024 revenue down 24% to $33.0M; operating loss widens to $21.1M
Revenue decreased 24.2% to $33.0M from $43.5M; domestic down 15.1%, international down 59.1%.
-
Retractable Technologies withdraws tariff complaint; engineers adapt equipment to reduce imports
Withdrew complaint in US Court of International Trade over 100% tariff on syringes/needles from China; case dismissed Jan 8, 2025.
-
Retractable Technologies declares dividends on Series II and III preferred stock
Series II Class B Preferred dividend: $39,050.00; Series III: $18,561.25.
-
Net sales $10.3M flat YoY; operating loss of $5.1M vs $936K loss last year.
-
USTR sets 100% tariff on Chinese syringes; Retractable files suit; declares preferred dividend
USTR finalized 100% tariff on Chinese syringes/needles effective Sept 27, 2024; Retractable sourced 91% from China in H1 2024.
-
Retractable Tech Q2 net sales $6.0M, operating loss $5.8M; tariff risk on China imports
Q2 net sales $6.0M, down 25% YoY; operating loss $5.8M vs $5.0M loss.
-
Retractable Technologies declares dividends on Series II and III preferred stock
Dividends of $39,050.00 (Series II) and $18,561.25 (Series III) on Class B Convertible Preferred Stock declared.
-
Retractable Technologies Q1 net sales fall to $7.6M; operating loss widens to $3.0M
Net sales $7.6M, down 31% from $11.0M in Q1 2023 due to lack of COVID vaccine syringe sales.
-
Retractable Technologies reports 2023 revenue down 54% to $43.6M, operating loss of $11.5M
Revenue $43.6M, down 54% YoY; domestic down 33.7%, international down 78.9%.
-
Retractable Technologies recalls 477,600 EasyPoint Needle units due to cannula detachment risk
Voluntary recall of EasyPoint Needle lot K220402 shipped within U.S. from July 20, 2022 to Sept 20, 2023.
-
Retractable Tech declares Q4 2023 preferred dividends: $39,050 Series II, $18,561 Series III
Series II Class B dividend of $39,050 and Series III Class B dividend of $18,561.25 declared.
-
FDA Safety Communication on Chinese syringes does not affect Retractable Technologies
FDA Safety Communication dated Nov 30, 2023, warns of quality issues with plastic syringes made in China.
-
Retractable Tech Q3 revenue drops 55% to $10.3M; operating loss widens to $936K
Net sales fell to $10.3M in Q3 2023 from $23.1M in Q3 2022, a 55% decline; nine-month sales $29.3M vs $82.1M.
-
Retractable Technologies declares Series II & III preferred dividends for Q3 2023
Dividends of $39,050.00 and $19,061.25 declared for Series II and Series III Class B Convertible Preferred Stock.
-
Q2 net sales $8.0M, down 44% from $14.3M; operating loss $5.0M vs $2.1M loss in prior year.
-
Retractable Technologies declares preferred dividends totaling $58,111 for Q2 2023
Series II Class B dividend $39,050; Series III Class B dividend $19,061.25.
-
Retractable Q1 2023 sales down 75% to $11.0M; operating loss of $2.7M vs $9.7M profit a year ago
Total net sales $11.0M for Q1 2023, vs $44.7M in Q1 2022; no U.S. government syringe orders.
-
Retractable Technologies announces annual meeting results; all three Class 1 directors elected
Shareholders elected Marco Laterza as Class I director with 18,949,698 votes for and 1,635,150 withheld.
-
Retractable Technologies 2022 revenue drops 49.7% to $94.8M; net income falls to $5.1M
Revenue $94.8M, down 49.7% YoY; domestic sales fell 68.8%, international up 105%.
-
Retractable Technologies cuts workforce 22%, expects $1.7M annual savings
Workforce reduced by approximately 22%, mainly in production, operations, and logistics.
-
Agreed to repurchase 3M shares from BML Investment Partners at $1.60/share, an 8% discount to $1.74 close on Dec 22, 2022.
-
Retractable Tech terminates 1.35M unvested options; reports stock price anomalies to SEC
Board terminated unvested option awards at $13.00/share to Shaw, Larios, and Fort III covering 1,350,000 shares.
-
Retractable Tech Q3 2022: operating loss $691k, net sales $23.1M, down 36% YoY
Operating loss of $691k in Q3 2022 vs income of $8.0M in Q3 2021.
-
Retractable Technologies declares preferred dividends totaling $58,111.25 for Q3 2022
Board declares $39,050 Series II and $19,061.25 Series III Class B preferred dividends.
-
Retractable Tech Q2 operating loss $2.1M; revenue $14.3M, down 66% YoY
Operating loss of $2.1M in Q2 2022 vs operating income of $12.7M in Q2 2021.
-
Retractable Technologies declares dividends on Series II and III Class B Preferred Stock
Board declared $39,050.00 dividend for Series II Class B Convertible Preferred Stock for Q2 2022.
-
Retractable Technologies cuts workforce 16%; expects annual savings of $2.1M
Workforce reduced by ~16%, primarily in production, operations, and logistics departments.
-
Operating income $9.7M vs $23.4M in Q1 2021; net sales $44.7M vs $50.1M.
-
Three Class 2 directors elected: Thomas J. Shaw (21,881,125 for), Walter O. Bigby, Jr. (21,060,688 for), John W. Fort III (21,690,144 for).
-
Retractable Technologies terminates $8.1M buyback plan; stock at discount to asset value
Effective April 14, 2022, terminated Rule 10b5-1 buyback plan dated June 4, 2021.
-
2021 revenues $188.4M vs $81.9M prior year (+130.1%); unit sales up 116.9%.
-
Retractable Technologies declares $78,545 in preferred stock dividends
Series II Class B preferred dividend of $39,050; Series III $39,495.
-
Retractable Technologies gets $6M modification to HHS contract for air freight costs
Modified contract 75A50121P00021 with HHS adds $6,000,000 funding for air freight through Jan 14, 2022.
-
Retractable posts $44.1M op income for 9 months, amends license deal with CEO
Operating income of $44.1M for nine months ended Sep 30, 2021, up from $11.8M in prior year.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.90 · Median 0.60 · Most common event earnings